Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DCTH vs CVM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DCTH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)
DCTH Overall Winner
6-Pillar Tally: DCTH 5 – 1 CVM
Matrix Metrics: DCTH 6 – 4 CVM
As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 0.0% operating margin) and revenue trajectory (+70.7% vs. -62.7% YoY).
- Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DCTH vs CVM
DCTH
Head-to-Head Winner
Delcath Systems Inc
$19.68
-4.23% 1D
Market Cap
$743.8M
TTM Revenue
$110M
Forward P/E
N/M
Beta / 30D Vol
1.63β · 131% Vol
Unified Composite Score
35.9
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
CVM
Cel-Sci Corporation
$1.59
+24.22% 1D
Market Cap
$20.9M
TTM Revenue
$28,558
Forward P/E
23.0x
Beta / 30D Vol
0.65β · 120% Vol
Unified Composite Score
56.6
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (DCTH 5 – 1 CVM)
1. Valuation Multiples
CVM
Forward P/E
N/M
23.0x
Trailing P/E
133.6x
23.0x
PEG Ratio
1.60x
1.12x
EV / Revenue
6.3x
N/M
2. Growth & Scale
DCTH
Revenue Growth (YoY)
+70.7%
-62.7%
Earnings Growth (YoY)
+750.0%
+0.0%
TTM Revenue (USD)
$110M
$28,558
Market Cap
$743.8M
$20.9M
3. Profitability & Quality
DCTH
Gross Margin
87.6%
N/A
Operating Margin
5.2%
0.0%
Net Profit Margin
6.0%
0.0%
Return on Equity (ROE)
5.4%
-252.5%
4. Balance Sheet & Cash Flow
DCTH
Cash Generation (TTM)
$20M
-$17M
Cash Flow Margin
18.3%
N/A
Net Cash / Leverage
$53M Net Cash
$6.6M Net Debt (1.24x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DCTH
Options Structure Phase
BREAKOUT
BREAKDOWN
Current IV / %ile
109.3% (43rd %ile)
N/A (N/A)
Put/Call OI Skew
0.11x (Call-Skewed)
N/A
OBV Trend / Tech Phase
ACCUMULATION · Neutral
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
DCTH
OpEx & R&D Intensity
82.4% of Rev ($91M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DCTH (6) vs CVM (4)| Institutional Metric | DCTH | CVM | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $743.8M | $20.9M | DCTH | |
| Trailing P/E Ratio | 133.6x | 23.0x | CVM | |
| Forward P/E Ratio | N/M | 23.0x | CVM | |
| Revenue Growth (YoY) | +70.7% | -62.7% | DCTH | |
| Operating Margin (TTM) | 5.2% | 0.0% | DCTH | |
| Net Profit Margin | 6.0% | 0.0% | DCTH | |
| Return on Equity (ROE) | 5.4% | -252.5% | DCTH | |
| 52-Week Range Position | 80% ($8–$23) | 10% ($1–$8) | DCTH | |
| Beta / 30D Volatility | 1.63β · 131% Vol | 0.65β · 120% Vol | CVM | |
| Unified Institutional Score | 35.9 / 100 (SELL) | 56.6 / 100 (HOLD) | CVM | |
| Trailing 12M Revenue (USD) | $110M | $28,558 | Scale | |
| Gross Profit Margin (TTM) | 87.6% | N/A | Quality | |
| PEG Ratio & EV / Revenue | 1.60x PEG · 6.3x EV/Rev | 1.12x PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $20M ($53M Net Cash) | -$17M ($6.6M Net Debt (1.24x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DCTH +50.94 pp
3M Horizon
DCTH +16.73 pp
6M Horizon
DCTH +85.02 pp
1Y Horizon
DCTH +196.36 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DCTH Revenue | CVM Revenue | DCTH Op. Margin | CVM Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2013 | $0M | $0M | -4179.6% | -12450.1% | DCTH |
| FY2014 | $0M | $0M | -1805.8% | -9721.4% | DCTH |
| FY2015 | $0M | N/A | -870.6% | N/A | DCTH |
| FY2021 | $0M | N/A | -690.0% | N/A | DCTH |
| FY2022 | $0M | N/A | -1245.1% | N/A | DCTH |
| FY2023 | $0M | N/A | -1849.0% | N/A | DCTH |
| FY2024 | $40M | N/A | -33.4% | N/A | DCTH |
| FY2025 | $90M | N/A | 0.8% | N/A | DCTH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DCTH
BREAKOUT
Current IV
109.3%
IV Percentile
43rd %ile
Put/Call OI Skew
0.11x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CVM
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DCTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
82.4% of Rev ($91M)
90D Engineering Disclosures
0 Published
CVM Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DCTH vs CVM Key Questions & Quantitative Answers
As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 0.0% operating margin) and revenue trajectory (+70.7% vs. -62.7% YoY). Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), DCTH cumulative revenue shifted +125.0% while CVM shifted N/A. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.
CVM screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus CVM (-252.5% ROE) capital efficiency.
In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CVM vs DCTH · Reverse Pair
DCTH vs CRMD
· Sector Peer
CVM vs AGEN
· Sector Peer
CVM vs BCRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking